Content page Template – H1

Lorem ipsum for subtitle text

H2 title

George Health is a revenue generating, rapidly expanding global business which is poised for significant growth. It delivers attractive investment opportunities to bring life extending treatments to the world’s biggest killers.

George Health’s business model is focussed on affordable, effective treatments with accelerated market delivery.

It provides long-term income opportunities with high growth potential, underwritten by established profitable and expanding business. George Health is seeking $40m of equity capital to be deployed over the next 3-5 years.

Pellentesque blandit ipsum et elementum efficitur.

Fusce porta cursus dignissim. Nunc bibendum orci vitae elementum ultrices. Phasellus pharetra quis tortor vitae tempor. Phasellus at tellus at risus volutpat varius. Mauris eget ligula gravida, rhoncus quam vitae, efficitur nisl. In imperdiet lectus efficitur nibh dignissim, nec laoreet massa elementum. Mauris consectetur ultrices massa, quis gravida arcu ornare ut. Nullam euismod luctus mi pretium hendrerit. Sed at odio dolor. Nam nec quam vel orci scelerisque feugiat. Sed accumsan metus elit, sed mattis elit pharetra sed. Nunc pulvinar gravida quam id aliquet. Vestibulum imperdiet venenatis odio, et gravida quam molestie vitae. Etiam orci neque, commodo et nisi eu, rhoncus commodo nisi.

Title section – h3

There are 2bn people in the world with one or more NCDs, including diabetes, high blood pressure (the leading cause of stroke), cancer and heart disease. Sufferers are currently underserved thanks to a lack of innovation, and complicated and expensive treatments. The number of sufferers is growing as populations age, presenting a huge human and financial challenge to patients, health providers and insurers alike – the accumulated costs associated with NCDs are expected to hit $47trn by 2030. [presentation p 3]

Pellentesque blandit ipsum et elementum efficitur.

Fusce porta cursus dignissim. Nunc bibendum orci vitae elementum ultrices. Phasellus pharetra quis tortor vitae tempor. Phasellus at tellus at risus volutpat varius. Mauris eget ligula gravida, rhoncus quam vitae, efficitur nisl. In imperdiet lectus efficitur nibh dignissim, nec laoreet massa elementum. Mauris consectetur ultrices massa, quis gravida arcu ornare ut. Nullam euismod luctus mi pretium hendrerit. Sed at odio dolor. Nam nec quam vel orci scelerisque feugiat. Sed accumsan metus elit, sed mattis elit pharetra sed. Nunc pulvinar gravida quam id aliquet. Vestibulum imperdiet venenatis odio, et gravida quam molestie vitae. Etiam orci neque, commodo et nisi eu, rhoncus commodo nisi.

$ 700

million

in research funding
and commercial
contracts.

There are 2bn people in the world with one or more NCDs, including diabetes, high blood pressure (the leading cause of stroke), cancer and heart disease. Sufferers are currently underserved thanks to a lack of innovation, and complicated and expensive treatments. The number of sufferers is growing as populations age, presenting a huge human and financial challenge to patients, health providers and insurers alike – the accumulated costs associated with NCDs are expected to hit $47trn by 2030. [presentation p 3]

$ 700

million

in research funding
and commercial
contracts.

$ 700

million

in research funding
and commercial
contracts.

$ 700

million

in research funding
and commercial
contracts.

Related Content

Find out more


Praesent nec consequat leo, eget vehicula purus. Ut venenatis semper auctor. Ut congue scelerisque nibh et dignissim. Interdum et malesuada fames ac ante ipsum primis in faucibus. Curabitur nec fringilla diam. Maecenas viverra purus sapien, sit amet dapibus mauris pretium ac.